Niu Teli: I le tali atu i se talosaga a le Fresenius Medical Care, ua fautuaina ai e le Komiti Faapitoa a Tagata Tomai Faapitoa (SEC) o le Faalapotopotoga Tutotonu o le Puleaina o Tulaga Faatonuina o Fualaau Faasaina (CDSCO) le kamupani e tuuina atu le mafuaaga mo le faamaoniga faatasi ai ma faamatalaga o suega faafomai vaega III o le calcium chloride dihydrate ma faamatalaga o le mataituina o le faatauina atu pe a uma ona faatauina atu mai atunuu ua faamaonia mo nisi iloiloga.
Sa faila muamua e le kamupani se talosaga e gaosia ma faʻatau atu le vailaʻau calcium chloride dihydrate i le malosi e 100 mmol/L, lea e faʻaaogaina mo le “togafitiga sui o le calcium i le togafitiga sui o fatugaʻo faifai pea (CRRT), dialysis faifai pea (i aso taʻitasi) (CLED) ma le fesuiaiga o le plasma therapeutic (TPE) faʻatasi ai ma le citrate anticoagulation. E talafeagai le oloa mo tagata matutua ma tamaiti” ma taʻua ai mafuaʻaga mo le faʻateʻaina mai suʻega faʻapitoa o le vaega III ma le vaega IV.
Na matauina e le komiti ua faamaonia le oloa i atunuu Europa e pei o Potukale, Peretania, Pasila, Sueteselani, Falani ma Tenimaka.
O le vaila'au o le calcium chloride dihydrate o le CaCl2 2H2O, o le calcium chloride lea e iai ni molekiu e lua o le vai i le iunite o le calcium chloride. O se mea e pa'epa'e ma tioata, e faigofie ona solo i le vai ma e hygroscopic, e mafai ona mitiia le susu mai le ea.
O le calcium chloride dihydrate o se vailaʻau e mafai ona faʻaaogaina o se faiga faʻamamā e faʻataʻapeʻape ai le chitin pe a faʻataʻapeʻapeina i le methanol. E taua tele lona sao i le talepeina o le fausaga tioata o le chitin ma e tele ona faʻaoga i le matāʻupu o le kemisi.
I le fonotaga a le SEC Nephrology na faia i le aso 20 o Me, 2025, na toe iloilo ai e le aufono se talosaga e faamaonia ai le gaosiga ma le maketiina o le 100 mmol/L calcium chloride dihydrate infusion solution mo le faaaogaina i le “calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (daily) dialysis (SLEDD), ma le therapeutic plasma exchange (TPE) with citrate anticoagulation. O le oloa ua faailoa mai i tagata matutua ma tamaiti” ma tuuina atu ai le faamaoniga mo tuusaunoaga mai tofotofoga faafomai vaega III ma le IV.
I le maeʻa ai o se talanoaga auiliili, na fautuaina ai e le komiti e tatau ona tuʻuina atu i le komiti le faʻavae mo le faʻamaoniga, faʻapea foʻi ma faʻamaumauga o suʻega faʻafomaʻi vaega III ma faʻamaumauga o le mataʻituina o le faʻalauiloaina pe a uma le maketiina mai atunuʻu ua faʻamaonia le vailaʻau, mo se isi iloiloga.
Faitau foi: Ua faamaonia e le CDSCO Group le Faailoga Faafouina mo le Myozyme a Sanofi, ma Talosaga mo se Iloiloga Faatonutonu
O Dr. Divya Kolin o se tagata ua faauu mai le PharmD ma e tele lona poto masani i togafitiga faafomai ma falemai faapea foi ma tomai sili ona lelei i suesuega faafomai ma togafitiga faafomai. Sa galue foi o ia o se fomai vailaau oncology i le matagaluega oncology i le Mysore Medical College and Research Institute. O loo ia tulituliloaina nei lana galuega i suesuega faafomai ma le pulega o faamatalaga faafomai. Ua galue o ia ma le Medical Dialogue talu mai Ianuari 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Na maua i le suʻesuʻega a le ABYSS o le taofia o beta-blockers ina ua maeʻa le myocardial infarction na mafua ai ona siʻitia le toto maualuga, tata o le fatu, ma faʻalavelave faʻaleaga o le cardiovascular: …